实用医学杂志2018，Vol.34Issue(3)：460-463,4.DOI:10.3969/j.issn.1006-5725.2018.03.030
CYP2C19基因多态性与阿那曲唑治疗绝经后乳腺癌患者疗效的相关性
Association of CYP2C19 gene polymorphism with anastrozole in treatment of postmenopausal breast can-cer patients
侯倩倩 1李玲玲 1王大庆 1杨虎 1谷巍1
作者信息
- 1. 河北省衡水市哈励逊国际和平医院肿瘤内科 河北衡水053000
- 折叠
摘要
Abstract
Objective To investigate the correlation between CYP2C19*2 gene polymorphism and efficacy of anastrozole in postmenopausal women with breast cancer. Methods The polymorphisms of CYP2C19*2 gene in postmenopausal women with postmenopausal breast cancer were detected by PCR. Results The A allele frequency of the CYP2C19*2 gene(OR=3.146,95% CI:1.244~7.275,P<0.05)was a risk factor for the efficacy of post-menopausal breast cancer patients.The survival rate was lower than that of GG(χ2=6.26,P<0.05).After treat-ment,the FSH and LH of GG patients were significantly lower than those of AA and GA(t=5.29,6.47,P<0.05). Multivariate logistic regression analysis showed that anastrozoleand CYP2C19*2 gene polymorphism were indepen-dently associated with serum FSH and LH levels in postmenopausal women with breast. Conclusion CYP2C19*2 gene polymorphism is associated with anastrozole in the treatment of postmenopausal breast cancer.关键词
绝经后乳腺癌/CYP2C19*2/基因多态性/阿那曲唑Key words
postmenopausal breast cancer/CYP2C19*2/gene polymorphism/anastrozole引用本文复制引用
侯倩倩,李玲玲,王大庆,杨虎,谷巍..CYP2C19基因多态性与阿那曲唑治疗绝经后乳腺癌患者疗效的相关性[J].实用医学杂志,2018,34(3):460-463,4.
